Australian and New Zealand FeLV guidelines: immune response shapes infection outcome, but key questions remain open
Australian veterinary journal · 2025
In plain language
This is a review of guidelines on feline leukaemia virus (FeLV) in pet cats in Australia and New Zealand. It describes how the outcome of infection depends partly on how each cat's immune system responds. In some cats the virus is cleared completely. In others, the body controls the virus in the blood, but viral genetic material may stay in the body for life. In others, the immune response is too weak and the virus stays in the blood. It is still not known whether "regressive" infection leads to disease later on.
Scientific detail
This publication is a consensus guideline (review) on the diagnosis, prevention and management of FeLV infection in domestic cats in Australia and New Zealand. It does not provide a new controlled immunological experiment; it summarises studies by other authors, and sample size is not reported for the review as a whole. The claims drawn from it carry evidence level C.
The review describes abortive infection as an effective immune response producing complete viral elimination after localised replication in the oropharyngeal lymph nodes. It does not identify a measured immune correlate that predicts this outcome, nor a way to induce it. In regressive infection, a partially effective immune response can clear primary viraemia without preventing lifelong infection through integrated proviral DNA; the source thus distinguishes immune control of circulating virus from elimination of integrated viral DNA, and clearance of viraemia does not establish eradication of infection.
In progressively infected cats, the review describes poor immune responsiveness resulting in lifelong persistent viraemia. This is a feline-specific pathogenesis statement rather than a controlled measurement of immune function, and the passage does not establish which immune defects are causal or quantify their individual contributions.
Regarding prognostic markers, a review cited by the guidelines did not identify useful prognostic value for neutrophil–lymphocyte, monocyte–lymphocyte or platelet–lymphocyte ratios in retrovirus-positive cats. The population is retrovirus-positive cats generally, not exclusively FeLV-infected cats, so this does not establish that every immune biomarker lacks prognostic value, or that these ratios were validated separately within each FeLV infection category.
The authors describe conflicting evidence on the prognosis of regressive infection and call for long-term studies. Lymphoma associations are reported alongside reviews suggesting life expectancy similar to uninfected cats; association is not proof of causation. Limited routine proviral testing in antigen-negative cats with lymphoma restricts retrospective investigation, and the literature on focal infection is limited, with some cases lacking longitudinal follow-up.
What we know
According to the review, the outcome of FeLV infection is linked to the cat's immune response: complete elimination in abortive infection, control of viraemia with persistent integrated proviral DNA in regressive infection, and lifelong persistent viraemia in progressive infection. Controlling viraemia is not the same as eliminating infection. This comes from a review of other studies (evidence level C), not a new experiment.
What we don't know
It is unresolved whether regressive infection contributes to later FeLV-related disease; the evidence conflicts. No immune marker with demonstrated prognostic value has been identified: the cell ratios assessed were not useful in retrovirus-positive cats. Which immune defects cause progressive infection is not established, and there is no measured immune correlate predicting viral elimination nor a known way to induce it. Long-term studies are lacking.
Evidence
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The review describes abortive FeLV infection as an effective immune response producing complete viral elimination after localised replication in oropharyngeal lymph nodes.
Excerpt verified in the source — verbatim, in the source's own language“Abortively infected cats mount an effective immune response that, after localised replication in the oropharyngeal lymph nodes, results in complete elimination of FeLV.”
This states the review's description of the abortive category. It does not identify a measured immune correlate that predicts this outcome or establish a way to induce it.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
The review describes poor immune responsiveness to FeLV in progressively infected cats as resulting in lifelong persistent viraemia.
Excerpt verified in the source — verbatim, in the source's own language“Progressively infected cats have a poor immune responsiveness to FeLV, resulting in permanent (lifelong) and persistent viraemia.”
This is a feline-specific pathogenesis statement in the review, not a new controlled measurement of immune function. The supplied passage does not establish which immune defects are causal or quantify their individual contributions.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
A review cited by the guidelines did not identify useful prognostic value for neutrophil–lymphocyte, monocyte–lymphocyte or platelet–lymphocyte ratios in retrovirus-positive cats.
Excerpt verified in the source — verbatim, in the source's own language“Recently, a review of three leukocyte ratios (neutrophil‐lymphocyte, monocyte‐lymphocyte and platelet‐lymphocyte) did not identify any that had useful prognostic value in retrovirus‐positive cats.”
The population is described as retrovirus-positive cats, not exclusively FeLV-infected cats. This does not establish that every immune biomarker lacks prognostic value or that these ratios were validated separately within each FeLV infection category.
EvidenceLevel C — Preliminary evidenceConfidence 100/100
In regressive FeLV infection, a partially effective immune response can clear primary viraemia without preventing lifelong infection through integrated proviral DNA.
Excerpt verified in the source — verbatim, in the source's own language“Regressively infected cats have a partially effective immune response against FeLV that clears a primary viraemia, typically within 4 months beyond initial infection, to prevent a secondary viraemia. The immune response is insufficient to prevent lifelong infection, however, due to a DNA copy of the RNA virus (called provirus) becoming integrated into the cat's own cellular DNA.”
The source distinguishes immune control of circulating virus from elimination of integrated viral DNA. Clearance of viraemia does not establish eradication of infection.
Open questionConfidence 100/100
The contribution of regressive FeLV infection to subsequent FeLV-related disease remains unresolved.
The regressive-infection section reports lymphoma associations alongside reviews suggesting similar life expectancy to uninfected cats. The authors call for long-term studies and causal investigation; association is not proof of causation.
Provenance
Source: Feline leukaemia virus (FeLV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.
AVA